Heparin-induced Thrombocytopenia.

Area of Science:

• Hematology
• Immunology
• Pharmacology

Background:

• Heparin treatment can cause thrombocytopenia, with immune-mediated HIT type II being the most severe.
• HIT type II necessitates immediate heparin cessation and alternative anticoagulation strategies.
• Diagnosis of HIT type II requires both clinical and laboratory evidence.

Purpose of the Study:

• To review the diagnostic criteria and management of heparin-induced thrombocytopenia (HIT type II).
• To discuss alternative anticoagulation options for patients with HIT type II, including hirudin and argatroban.
• To highlight the challenges in managing HIT type II, particularly in patients undergoing coronary artery bypass graft surgery.

Main Methods:

• Review of clinical and laboratory diagnostic criteria for HIT type II.
• Evaluation of alternative anticoagulants like hirudin and argatroban for HIT type II.
• Assessment of laboratory testing for HIT antibody cross-reactivity with danaparoid and low molecular weight heparin.

Main Results:

• Hirudin and argatroban are approved alternatives with no cross-reactivity with HIT antibodies.
• Laboratory evaluation is essential to confirm HIT type II and assess antibody cross-reactivity.
• No ideal heparin alternative exists for HIT type II patients requiring coronary artery bypass graft surgery.

Conclusions:

• HIT type II is a critical condition requiring prompt diagnosis and management.
• Alternative anticoagulants are available, but challenges remain, especially for surgical patients.
• Further research is needed to identify ideal anticoagulation strategies for complex HIT type II cases.